SEARCH

SEARCH BY CITATION

References

  • 1
    Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:164552.
  • 2
    Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008;19:8118.
  • 3
    Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:101322.
  • 4
    Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 2002;59:6594.
  • 5
    Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost–effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001;10:60115.
  • 6
    Kanis J, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399428.
  • 7
    Schousboe J. Cost effectiveness of screen-and-treat strategies for low bone mineral density: how do we screen, who do we screen and who do we treat? Appl Health Econ Health Policy 2008;6:118.
  • 8
    Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int 2007;18:148191.
  • 9
    Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost–effective for elderly women. J Am Geriatr Soc 2005;53:1697704.
  • 10
    Schousboe JT, Taylor BC, Fink HA, et al. Cost–effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007;298:62937.
  • 11
    Hiligsmann M, Ethgen O, Bruyere O, et al. An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis. Dis Manage Health Outcomes 2008;16:42938.
  • 12
    Mueller D, Gandjour A. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Appl Health Econ Health Policy 2008;6:11335.
  • 13
    Stevenson M, Lloyd Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1160.
  • 14
    Van Staa TP, Kanis JA, Geusens P, et al. The cost–effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. Value Health 2007;10:34857.
  • 15
    Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 2008;26:51336.
  • 16
    Schott AM, Ganne C, Hans D, et al. Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int 2007;18:14351.
  • 17
    Borgstrom F, Johnell O, Kanis JA, et al. At what hip fracture risk is it cost–effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 2006;17:145971.
  • 18
    Hiligsmann M, Ethgen O, Bruyère O, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009;12:68796.
  • 19
    Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:38597.
  • 20
    National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC. 2008, Available at http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf[Accessed April 1, 2009].
  • 21
    Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001;19:118597.
  • 22
    Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:447.
  • 23
    Strom O, Borgstrom F, Kanis JA, et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 2009;20:2334.
  • 24
    Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:46889.
  • 25
    Hiligsmann M, Bruyere O, Ethgen O, et al. Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 2008;43:99194.
  • 26
    Dere W, Avouac B, Boers M, et al. Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcif Tissue Int 1998;63:937.
  • 27
    Cleemput I, Van Wilder P, Huybrechts M, et al. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009;12:4419.
  • 28
    Zethraeus N, Borgstrom F, Strom O, et al. Cost–effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. Osteoporos Int 2007;18:923.
  • 29
    Hiligsmann M, Ethgen O, Richy F, et al. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 2008;82:28892.
  • 30
    Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000;27:58590.
  • 31
    Boonen S, Kaufman JM, Reginster JY, et al. Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium. Osteoporos Int 2003;14:1105.
  • 32
    Marshall D, Johnell O, Wedel H Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:12549.
  • 33
    Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:118594.
  • 34
    National Institute for Health and Clinical Excellence (NICE). Systematic reviews of clinical effectiveness prepared for the guideline “Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk:” National Institute for Health and Clinical Excellence, 2008. Available from: http://nice.org.uk/nicemedia/pdf/OsteoporosisEvidenceReviews190908.pdf[Accessed April 5, 2009].
  • 35
    Stock JL, Bell NH, Chesnut CH, 3rd, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:2917.
  • 36
    Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85:310915.
  • 37
    Tosteson AN, Jonsson B, Grima DT, et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 2001;12:84957.
  • 38
    Strom O, Borgstrom F, Sen SS, et al. Cost–effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007;18:104761.
  • 39
    Belgian Center for Pharmacotherapeutic Information. Drug directory: bisphosphonates. Available from: http://www.cbip.be/GGR/MPG/MPG_NI.cfm#MP_04090[Accessed April 5, 2009].
  • 40
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:153541.
  • 41
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:207782.
  • 42
    Belgian Center for Pharmacotherapeutic Information. Drug directory: calcium and vitamin D. Available from: http://www.cbip.be/GGR/MPG/MPG_KAC.CFM#MP_1904[Accessed April 5, 2009].
  • 43
    Hiligsmann M, Bruyere O, Pire G, et al. Economic evaluation of osteoporosis screening strategy conducted in the Province of Liege with the cooperation of Liege Province Sante. Rev Med Liege 2008;63:58894.
  • 44
    Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;122:S313.
  • 45
    Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:9228.
  • 46
    Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 2009;10:230315.
  • 47
    Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:102331.
  • 48
    Cleemput I, Neyt M, Thiry N, et al. Valeurs seuils pour le rapport coût-efficacité en soins de santé. Health Technology Assessment (HTA). Bruxelles: Centre fédéral d'expertise des soins de santé (KCE) 2008. KCE Reports 100B (D/2008/10.273/95).
  • 49
    Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New-York: Oxford University Press, 2006.
  • 50
    Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009;in press. doi:10.1007/s00198-009-0976-0.
  • 51
    Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007;18:131117.
  • 52
    Reginster JY, Rabenda V, Neuprez A Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006;38(Suppl 1):S26.
  • 53
    Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007;120:2516.
  • 54
    Sambrook P. Compliance with treatment in osteoporosis patients—an ongoing problem. Aust Fam Physician 2006;35:1357.